Prellis Biologics Launches In Vitro Human Antibody Discovery Platform, Announces $14.5 Million Series B Investment, Key Executive Hires

SAN FRANCISCO: SAN FRANCISCO, Dec. 15, 2021 /PRNewswire-PRWeb/ -- Prellis Biologics announced today that it has closed a $14.5 million Series B financing round, led by Celesta Capital and current investor Khosla Ventures Prellis will use the proceeds to advance its Externalized Immune System (EXIS™) platform, a first-in-class in vitro,...

Click to view original post